Related Experiment Video
Updated: Jan 22, 2026

Inducing Complete Polyp Regeneration from the Aboral Physa of the Starlet Sea Anemone Nematostella vectensis
Published on: January 14, 2017
A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps
Christopher D Codispoti1, Mahboobeh Mahdavinia1
1Rush University, Chicago, Illinois.
Objective:
To identify the need for cost-effectiveness analysis of biologic therapies in the treatment of chronic rhinosinusitis (CRS).
Data Sources:
Clinical trials of monoclonal antibodies (omalizumab, benralizumab, mepolizumab and dupilumab) for nasal polyposis or chronic rhinosinusitis published on PubMed.
Study Selections:
Clinical trials of biologic therapies in CRS and nasal polyposis.
Results:
No cost-effectiveness analyses of biologic therapies in CRS have been performed.
Conclusion:
As more clinical trials of biologic therapies for CRS are conducted, there is a need for cost-effectiveness analysis. Future analyses should consider these therapies as part of medical therapeutic options compared with surgery. To increase generalizability, analyses should include samples from allergy and primary care clinics rather than only otolaryngology clinics.
More Related Videos
Related Concept Videos
Biological Effects of Radiation
Gene Therapy
Nose and Nasal Cavity
What is Conservation Biology?
Administering Oxygen by Nasal Cannula
Nasal Cannulas
A nasal cannula is a lightweight tube split into two prongs placed in the nostrils,...
Oxygen Delivering System I: Nasal Cannula and Face Mask
Nasal Cannula
A nasal cannula is a lightweight tube split at one end into two prongs and placed in the nostrils. It is typically used to deliver low to medium levels of oxygen.
Suggested flow rate: The suggested flow rate for a nasal cannula typically ranges between 1 and 6 L/min.
Oxygen percentage setting:...

